May 6 (Reuters) - The U.S. Food and Drug Administration's panel of independent advisers will on June 4 deliberate whether they should recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder, Lykos Therapeutics said on Monday.
(Reporting by Pratik Jain in Bengaluru; Editing by Krishna Chandra Eluri)
